Shire PLC (NASDAQ:SHPG) – Investment analysts at SunTrust Banks raised their Q2 2017 earnings per share estimates for Shire PLC in a report issued on Wednesday. SunTrust Banks analyst J. Boris now anticipates that the biopharmaceutical company will post earnings of $3.62 per share for the quarter, up from their prior estimate of $3.59.

Other research analysts have also recently issued research reports about the stock. Royal Bank Of Canada set a $221.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research report on Thursday, May 18th. Jefferies Group LLC set a $239.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research report on Thursday, April 20th. Stifel Nicolaus lowered their price target on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Finally, ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Shire PLC has a consensus rating of “Buy” and a consensus price target of $223.18.

COPYRIGHT VIOLATION WARNING: “Shire PLC (SHPG) Forecasted to Earn Q2 2017 Earnings of $3.62 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/shire-plc-shpg-forecasted-to-earn-q2-2017-earnings-of-3-62-per-share.html.

Shire PLC (NASDAQ SHPG) opened at 155.91 on Monday. Shire PLC has a 12 month low of $155.06 and a 12 month high of $209.22. The firm has a market capitalization of $46.44 billion, a price-to-earnings ratio of 159.91 and a beta of 1.60.

Shire PLC (NASDAQ:SHPG) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.53 by $0.20. Shire PLC had a net margin of 4.70% and a return on equity of 14.32%. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.73 billion. During the same quarter in the prior year, the business earned $3.38 earnings per share. Shire PLC’s revenue for the quarter was up 54.2% on a year-over-year basis.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dumont & Blake Investment Advisors LLC raised its stake in shares of Shire PLC by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 2,594 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 7 shares during the period. Inspirion Wealth Advisors LLC raised its stake in shares of Shire PLC by 0.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 8 shares during the period. Level Four Advisory Services LLC raised its stake in shares of Shire PLC by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 13 shares during the period. Thompson Davis & CO. Inc. raised its stake in shares of Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the period. Finally, Macquarie Group Ltd. raised its stake in shares of Shire PLC by 2.2% in the fourth quarter. Macquarie Group Ltd. now owns 1,417 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 31 shares during the period. 21.05% of the stock is currently owned by institutional investors.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History and Estimates for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.